Members

Dr. Poznansky is an expert physician scientist and medical innovator who has combined these expertise together to found and direct the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital to foster accelerated bench to bedside research and the development of novel vaccines and immunotherapies for cancer, infectious and immune mediated diseases. His expertise is in immunology and, in particular, immune cell migration. Dr. Poznansky discovered fugetaxis, the principle of immuno-repulsion or the active movement of immune cells away from an agent source, that forms the basis of his academic research at Harvard Medical School. His laboratory defined the molecular mechanism for this novel immune process and now explores the relevance of this mechanism to new therapeutic approaches to cancer, infectious diseases and type 1 diabetes.

The goal of VIC is to enable efficient and rapid transition of promising technologies through preclinical development and into the clinical stage of development through technology spin outs, partnerships or out-licensing. The team at VIC has developed a novel high dimensional immunology program that uses state of the art omics technologies to define broad immune profiles in cancer, infectious and immune mediated diseases to inform diagnosis, clinical decision making and vaccine and immunotherapy design. Dr. Poznansky is the scientific founder of Celtaxys, ACTx, Vicapsys, Aperisys, B-Genesys and Voltron Therapeutics.
Dr. Poznansky is an Associate Professor of Medicine at Harvard Medical School and Attending Physician in Infectious Diseases Medicine at Massachusetts General Hospital. He obtained his B.Sc. and his MD at the University of Edinburgh and his PhD in Medical Sciences at Cambridge University. He also served as a Resident in Clinical Immunology at the Addenbrooke’s Hospital in Cambridge, UK and a Captain in the Royal Army Medical Corps. He completed his post-doctoral research training in retrovirology at Harvard Medical School and the Dana Farber Cancer Institute. He completed his infectious diseases fellowship training at Imperial College and Harvard Medical School.